Literature DB >> 25311082

Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.

Hugo J A Adams1, John M H de Klerk2, Rob Fijnheer3, Ben G F Heggelman4, Stefan V Dubois5, Rutger A J Nievelstein1, Thomas C Kwee1.   

Abstract

PURPOSE: This study aimed to determine the prognostic value of whole-body maximum standardized uptake value (SUVmax ), whole-body metabolic tumor volume (MTV), and whole-body total lesion glycolysis (TLG) at pretreatment (18) F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG-PET/CT) in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).
MATERIALS AND METHODS: Seventy-three patients with newly diagnosed DLBCL who had undergone FDG-PET/CT before rituximab, cyclophosphamide, hydroxydaunorubicin, oncovin, and prednisolone (R-CHOP) immunochemotherapy were retrospectively included. All FDG-avid lesions in each patient were segmented using semi-automated software to calculate whole-body SUVmax , whole-body MTV, and whole-body TLG values. Cox regression analyses were used to determine the associations of whole-body SUVmax , whole-body MTV, whole-body TLG, and dichotomized National Comprehensive Cancer Network International Prognostic Index (NCCN-IPI) risk group (low risk vs. high risk) with progression-free survival (PFS) and overall survival (OS).
RESULTS: On univariate Cox regression analysis, only the NCCN-IPI was a significant predictor of PFS (P = 0.024), and only the NCCN-IPI and whole-body MTV were significant predictors of OS (P = 0.039 and P = 0.043, respectively). In the multivariate Cox proportional hazards model, only the NCCN-IPI remained an independent predictive factor of PFS (P = 0.024) and OS (P = 0.039).
CONCLUSION: Whole-body SUVmax , whole-body MTV, and whole-body TLG do not provide any prognostic information in DLBCL beyond that which can already be obtained by the NCCN-IPI. Therefore, the NCCN-IPI remains the most important prognostic tool in this disease.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography; National Comprehensive Cancer Network International Prognostic Index; diffuse large B-cell lymphoma; prognosis; survival; total lesion glycolysis

Mesh:

Substances:

Year:  2015        PMID: 25311082     DOI: 10.1111/ejh.12467

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  21 in total

Review 1.  Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations.

Authors:  Catherine S Diefenbach; Joseph M Connors; Jonathan W Friedberg; John P Leonard; Brad S Kahl; Richard F Little; Lawrence Baizer; Andrew M Evens; Richard T Hoppe; Kara M Kelly; Daniel O Persky; Anas Younes; Lale Kostakaglu; Nancy L Bartlett
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

2.  Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI.

Authors:  Qaid Ahmed Shagera; Gi Jeong Cheon; Youngil Koh; Min Young Yoo; Keon Wook Kang; Dong Soo Lee; E Edmund Kim; Sung-Soo Yoon; June-Key Chung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-02       Impact factor: 9.236

3.  PET-derived tumor metrics predict DLBCL response and progression-free survival.

Authors:  Prioty Islam; Jordan Goldstein; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2019-02-04

4.  Metabolic Tumor Volume in Lymphoma: Hype or Hope?

Authors:  Heiko Schöder; Craig Moskowitz
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

5.  Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants.

Authors:  Mixue Xie; Kefei Wu; Yan Liu; Qi Jiang; Yanhui Xie
Journal:  Med Oncol       Date:  2014-12-16       Impact factor: 3.064

6.  Discovery of Pre-Treatment FDG PET/CT-Derived Radiomics-Based Models for Predicting Outcome in Diffuse Large B-Cell Lymphoma.

Authors:  Russell Frood; Matthew Clark; Cathy Burton; Charalampos Tsoumpas; Alejandro F Frangi; Fergus Gleeson; Chirag Patel; Andrew F Scarsbrook
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

7.  The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.

Authors:  Zahra Kiamanesh; Narjess Ayati; Ramin Sadeghi; Eliza Hawkes; Sze Ting Lee; Andrew M Scott
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08-06       Impact factor: 10.057

8.  Two-Year Event-Free Survival Prediction in DLBCL Patients Based on In Vivo Radiomics and Clinical Parameters.

Authors:  Zsombor Ritter; László Papp; Katalin Zámbó; Zoltán Tóth; Dániel Dezső; Dániel Sándor Veres; Domokos Máthé; Ferenc Budán; Éva Karádi; Anett Balikó; László Pajor; Árpád Szomor; Erzsébet Schmidt; Hussain Alizadeh
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

9.  SAKK38/07 study: integration of baseline metabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model.

Authors:  Luca Ceriani; Giuseppe Gritti; Luciano Cascione; Maria Cristina Pirosa; Angela Polino; Teresa Ruberto; Anastasios Stathis; Andrea Bruno; Alden A Moccia; Luca Giovanella; Stefanie Hayoz; Sämi Schär; Stefan Dirnhofer; Alessandro Rambaldi; Giovanni Martinelli; Christoph Mamot; Emanuele Zucca
Journal:  Blood Adv       Date:  2020-03-24

10.  Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.

Authors:  Honghui Huang; Fei Xiao; Xiaofeng Han; Lu Zhong; Hua Zhong; Lan Xu; Jianyi Zhu; Beiwen Ni; Jia Liu; Yi Fang; Minyue Zhang; Lijing Shen; Ting Wang; Jianjun Liu; Yiping Shi; Yumei Chen; Luying Zheng; Qiang Liu; Fangyuan Chen; Jianmin Wang
Journal:  Nucl Med Commun       Date:  2016-07       Impact factor: 1.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.